Type 3 Diabetes: A Molecular Link Between Cerebral Insulin Resistance and Neurodegeneration via AGE-RAGE Signaling.
Level 5 - mechanism / opinion, no new human data
Narrative review of molecular mechanisms without original human clinical data or systematic synthesis.
PubMed 41459736 · doi:10.1111/ejn.70364
What was done
This narrative review synthesized molecular literature regarding the pathological link between type 2 diabetes mellitus and Alzheimer's disease (termed Type 3 diabetes). It specifically examined the roles of cerebral insulin resistance, impaired Akt and GLUT-3/4 signaling, and downstream activation of the AGE-RAGE-NF-κB signaling axis and associated transcription pathways in driving neurodegeneration.
What was found
The abstract reports no quantitative findings or empirical effect sizes. It describes a mechanistic cascade where cerebral insulin resistance disrupts Akt signaling, GSK-3β activity, mitochondrial function, GLUT-3/4 translocation, and amyloid-β clearance, promoting tau hyperphosphorylation and plaque accumulation. Concurrently, AGE-RAGE signaling engages MAPK, ERK1/2, and JNK/STAT pathways and activates transcription factors (NF-κB, TGF-β, HIF-1α, AP-1), which accelerates neuroinflammation, oxidative stress, and cognitive decline. Natural bioactive compounds are discussed as potential modulators of this axis.
Why it matters
It outlines how metabolic dysfunction and advanced glycation end-product signaling may converge to accelerate Alzheimer's disease pathology, identifying the AGE-RAGE axis as a potential target for therapeutic intervention.
Limits
The paper is a narrative review providing mechanistic models rather than primary empirical data. No systematic search criteria, sample sizes, clinical trial results, or quantitative metrics are reported in the abstract.
Cited by
- supports Alzheimer's disease is biologically characterized in many ways as type 3 diabetes.